List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1464879/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Apigenin Modulates Dendritic Cell Activities and Curbs Inflammation Via RelB Inhibition in the Context of Neuroinflammatory Diseases. Journal of NeuroImmune Pharmacology, 2021, 16, 403-424.	4.1	22
2	pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer. Molecular Pharmaceutics, 2021, 18, 87-100.	4.6	31
3	Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection. Frontiers in Immunology, 2021, 12, 608890.	4.8	8
4	Risk Factors Associated with the Clinical Outcomes of COVID-19 and Its Variants in the Context of Cytokine Storm and Therapeutics/Vaccine Development Challenges. Vaccines, 2021, 9, 938.	4.4	4
5	Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?. Journal of NeuroImmune Pharmacology, 2021, , 1.	4.1	2
6	Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers, 2021, 13, 5059.	3.7	39
7	Human T-cell Leukemia Virus Type 1 and Strongyloides stercoralis: Partners in Pathogenesis. Pathogens, 2020, 9, 904.	2.8	18
8	Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics. , 2020, , 1-120.		3
9	Human T cell leukemia virus type 1 and Zika virus: tale of two reemerging viruses with neuropathological sequelae of public health concern. Journal of NeuroVirology, 2019, 25, 289-300.	2.1	2
10	Hepatitis C Virus Infection: Host–Virus Interaction and Mechanisms of Viral Persistence. Cells, 2019, 8, 376.	4.1	85
11	Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin. Antioxidants, 2019, 8, 35.	5.1	291
12	MEF-2 isoforms' (A-D) roles in development and tumorigenesis. Oncotarget, 2019, 10, 2755-2787.	1.8	12
13	Functional Meningeal Lymphatics and Cerebrospinal Fluid Outflow. Journal of NeuroImmune Pharmacology, 2018, 13, 123-125.	4.1	9
14	FDC:TFH Interactions within Cervical Lymph Nodes of SIV-Infected Rhesus Macaques. Journal of NeuroImmune Pharmacology, 2018, 13, 204-218.	4.1	12
15	Diminished TLR2-TLR9 mediated CD4+ T cell responses are associated with increased inflammation in	3.3	8
16	Follicular Dendritic Cells of Lymph Nodes as Human Immunodeficiency Virus/Simian Immunodeficiency Virus Reservoirs and Insights on Cervical Lymph Node. Frontiers in Immunology, 2018, 9, 805.	4.8	13
17	In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection. Vaccine, 2018, 36, 5046-5057.	3.8	13
18	Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity. Scientific Reports, 2017, 7, 2707.	3.3	29

#	Article	IF	CITATIONS
19	HTLV-1 Infection and Neuropathogenesis in the Context of Rag1-/-γc-/- (RAG1-Hu) and BLT Mice. Journal of NeuroImmune Pharmacology, 2017, 12, 504-520.	4.1	14
20	Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget, 2017, 8, 81754-81775.	1.8	32
21	Update on Gender Equity in Immunology, 2001 to 2016. Journal of Immunology, 2016, 197, 3751-3753.	0.8	2
22	Apigenin, a Natural Flavonoid, Attenuates EAE Severity Through the Modulation of Dendritic Cell and Other Immune Cell Functions. Journal of NeuroImmune Pharmacology, 2016, 11, 36-47.	4.1	66
23	Short Communication: Inhibition of DC-SIGN-Mediated HIV-1 Infection by Complementary Actions of Dendritic Cell Receptor Antagonists and Env-Targeting Virus Inactivators. AIDS Research and Human Retroviruses, 2016, 32, 93-100.	1.1	10
24	Inhibition of Endoplasmic Reticulum-Resident Glucosidases Impairs Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 Spike Protein-Mediated Entry by Altering the Glycan Processing of Angiotensin I-Converting Enzyme 2. Antimicrobial Agents and Chemotherapy, 2015, 59, 206-216.	3.2	63
25	IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment. Journal of Interferon and Cytokine Research, 2015, 35, 698-709.	1.2	12
26	Myocyte enhancer factor (MEF)-2 plays essential roles in T-cell transformation associated with HTLV-1 infection by stabilizing complex between Tax and CREB. Retrovirology, 2015, 12, 23.	2.0	15
27	Targeting the C-type Lectins-Mediated Host-Pathogen Interactions with Dextran. Journal of Pharmacy and Pharmaceutical Sciences, 2014, 17, 371.	2.1	97
28	Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. Journal of Clinical & Cellular Immunology, 2014, 05, .	1.5	1
29	In vivo immunogenicity of Tax(11–19) epitope in HLA-A2/DTR transgenic mice: Implication for dendritic cell-based anti-HTLV-1 vaccine. Vaccine, 2014, 32, 3274-3284.	3.8	16
30	Human T-lymphotropic Virus Type 1-infected Cells Secrete Exosomes That Contain Tax Protein. Journal of Biological Chemistry, 2014, 289, 22284-22305.	3.4	134
31	Effect of morphine and SIV on dendritic cell trafficking into the central nervous system of rhesus macaques. Journal of NeuroVirology, 2014, 20, 175-183.	2.1	15
32	Lack of Recall Response to Tax in ATL and HAM/TSP Patients But Not in Asymptomatic Carriers of Human T-cell Leukemia Virus Type 1. Journal of Clinical Immunology, 2013, 33, 1223-1239.	3.8	17
33	Epigenetics, Drugs of Abuse, and the Retroviral Promoter. Journal of Neurolmmune Pharmacology, 2013, 8, 1181-1196.	4.1	17
34	An Altered Maturation and Adhesion Phenotype of Dendritic Cells in Diseased Individuals Compared to Asymptomatic Carriers of Human T Cell Leukemia Virus Type 1. AIDS Research and Human Retroviruses, 2013, 29, 1273-1285.	1.1	13
35	Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?. Virology: Research and Treatment, 2013, 4, VRT.S11046.	3.5	8
36	HTLV-1 Infection and Its Associated Diseases. Leukemia Research and Treatment, 2012, 2012, 1-1.	2.0	12

#	Article	IF	CITATIONS
37	Cotranscriptional Chromatin Remodeling by Small RNA Species: An HTLV-1 Perspective. Leukemia Research and Treatment, 2012, 2012, 1-15.	2.0	7
38	Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood–brain barrier through paracellular transmigration and ERK activation. Journal of Neuroinflammation, 2012, 9, 245.	7.2	88
39	Unique and differential protein signatures within the mononuclear cells of HIV-1 and HCV mono-infected and co-infected patients. Clinical Proteomics, 2012, 9, 11.	2.1	24
40	HTLV-1 Tax Mediated Downregulation of miRNAs Associated with Chromatin Remodeling Factors in T Cells with Stably Integrated Viral Promoter. PLoS ONE, 2012, 7, e34490.	2.5	36
41	Mechanisms of Dendritic Cell Trafficking Across the Blood–brain Barrier. Journal of NeuroImmune Pharmacology, 2012, 7, 74-94.	4.1	49
42	The Tug-of-War between Dendritic Cells and Human Chronic Viruses. International Reviews of Immunology, 2011, 30, 341-365.	3.3	9
43	Murine FLT3 Ligand-Derived Dendritic Cell-Mediated Early Immune Responses Are Critical to Controlling Cell-Free Human T Cell Leukemia Virus Type 1 Infection. Journal of Immunology, 2011, 186, 390-402.	0.8	18
44	Unique Cytokine/Chemokine Signatures for HIV-1 and HCV Mono- Infection versus Co-infection as Determined by the Luminex? Analyses. Journal of Clinical & Cellular Immunology, 2011, 2, .	1.5	19
45	Depletion of Dendritic Cells Enhances Susceptibility to Cell-Free Infection of Human T Cell Leukemia Virus Type 1 in CD11c-Diphtheria Toxin Receptor Transgenic Mice. Journal of Immunology, 2010, 184, 5553-5561.	0.8	19
46	α4β1 Integrin Mediates the Recruitment of Immature Dendritic Cells across the Blood-Brain Barrier during Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2010, 184, 7196-7206.	0.8	96
47	Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease. Journal of Leukocyte Biology, 2009, 86, 1205-1216.	3.3	23
48	DC-SIGN Mediates Cell-Free Infection and Transmission of Human T-Cell Lymphotropic Virus Type 1 by Dendritic Cells. Journal of Virology, 2009, 83, 10908-10921.	3.4	76
49	Identification of Human T Cell Leukemia Virus Type 1 Tax Amino Acid Signals and Cellular Factors Involved in Secretion of the Viral Oncoprotein. Journal of Biological Chemistry, 2007, 282, 34581-34593.	3.4	27
50	Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1. Journal of Leukocyte Biology, 2007, 82, 44-56.	3.3	38
51	Interaction of HTLV-1 Tax protein with calreticulin: Implications for Tax nuclear export and secretion. Biomedicine and Pharmacotherapy, 2007, 61, 194-200.	5.6	30
52	A novel high throughput quantum dot-based fluorescence assay for quantitation of virus binding and attachment. Journal of Virological Methods, 2007, 141, 125-132.	2.1	42
53	Use of human antigen presenting cell gene array profiling to examine the effect of human T-cell leukemia virus type 1 Tax on primary human dendritic cells. Journal of NeuroVirology, 2006, 12, 47-59.	2.1	24
54	CCAAT/enhancer-binding proteins modulate human T cell leukemia virus type 1 long terminal repeat activation. Virology, 2006, 348, 354-369.	2.4	24

#	Article	IF	CITATIONS
55	AP-1-directed human T cell leukemia virus type 1 viral gene expression during monocytic differentiation. Journal of Leukocyte Biology, 2006, 80, 640-650.	3.3	17
56	Regulation of Human T-Cell Leukemia Virus Type 1 Gene Expression by Sp1 and Sp3 Interaction with TRE-1 Repeat III. DNA and Cell Biology, 2006, 25, 262-276.	1.9	11
57	HTLV-1 Tax nucleocytoplasmic shuttling, interaction with the secretory pathway, extracellular signaling, and implications for neurologic disease. Journal of Biomedical Science, 2005, 12, 961-974.	7.0	42
58	Human T-cell leukemia virus type I Tax induces the expression of dendritic cell markers associated with maturation and activation. Journal of NeuroVirology, 2004, 10, 358-371.	2.1	34
59	Cyclic AMP Signaling Pathway Modulates Susceptibility of Candida Species and Saccharomyces cerevisiae to Antifungal Azoles and Other Sterol Biosynthesis Inhibitors. Antimicrobial Agents and Chemotherapy, 2003, 47, 3195-3201.	3.2	73